LPRI shows good value in predicting and excluding advanced fibrosis and cirrhosis in patients with CHB combined with NAFLD, and can reduce diagnostic uncertainty for advanced fibrosis, thereby decreasing unnecessary liver biopsies and improving screening efficiency.
Wang et al. (Wed,) studied this question.